N-(3,5-二溴-4-羟基苯基)乙酰胺 | 63558-07-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3,5-二溴-4-羟基苯基)乙酰胺
• 英文名称: 2,6-Dibrom-4-acetamidophenol
• 英文别名: N-(3,5-dibromo-4-hydroxyphenyl)acetamide；acetic acid-(3,5-dibromo-4-hydroxy-anilide)；Essigsaeure-(3,5-dibrom-4-hydroxy-anilid)；2.6-Dibrom-4-acetamino-phenol
• CAS: 63558-07-6
• 化学式: C₈H₇Br₂NO₂
• 分子量: 308.957
• InChiKey: APHFPJMCRQLKSY-UHFFFAOYSA-N

物化性质

• 沸点：
  375.8±42.0 °C(Predicted)
• 密度：
  2.015±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3,5-二溴-4-羟基苯基)乙酰胺 在 盐酸 、 potassium carbonate 作用下， 以 水 、 丙酮 为溶剂， 反应 0.67h， 生成 3,5-二溴-4-甲氧基苯胺
  参考文献：
  名称：

  Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A–1

  摘要：

  The antiproliferative activity on ovarian cancer (SK-OV-3) cells of a series of triazole-bridged combretastatin analogues (37, 38, 40-43) containing dihalogenation of the A-ring is reported, and compared with their trimethoxy analogues (5, 15, 39). It was found that dihalogenation with either bromine or iodine was a tolerated modification when compared to the parent compound combretastatin (CA-4, 1) and had less effect than B-ring modification on potency. These compounds exhibited G(2)/M arrest, and maintained antitubulin activity. Further assays on human umbilical vein endothelial cells (HUVECs) demonstrated the potential antivascular effects of these triazoles. Of particular note was a 3,5-diiodo-4-methoxyaryl triazole (43) which had promising 7-fold selectivity for HUVECs over ovarian cancer cells. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.010
• 作为产物：
  描述：

  对乙酰氨基酚 在 氯仿 、 溴 作用下， 生成 N-(3,5-二溴-4-羟基苯基)乙酰胺
  参考文献：
  名称：

  Fuchs, Monatshefte fur Chemie, 1917, vol. 38, p. 337

  摘要：

  DOI：

文献信息

• A scalable and green one-minute synthesis of substituted phenols
  作者：Vijayaragavan Elumalai、Jørn H. Hansen

  DOI：10.1039/d0ra08580d

  日期：——

  highly efficient protocol was developed for the synthesis of substituted phenols via ipso-hydroxylation of arylboronic acids in ethanol. The method utilizes the combination of aqueous hydrogen peroxide as the oxidant and H2O2/HBr as the reagent under unprecedentedly simple and convenient conditions. A wide range of arylboronic acids were smoothly transformed into substituted phenols in very good to

  开发了一种温和、绿色和高效的方案，用于通过乙醇中芳基硼酸的同羟基化合成取代酚。该方法利用过氧化氢水溶液作为氧化剂和H 2 O 2 /HBr作为试剂的组合，在前所未有的简单方便的条件下进行。多种芳基硼酸无需色谱纯化即可顺利转化为取代苯酚，产率从非常好到极好。该反应在室温下可扩展至至少 5 克，反应时间为 1 分钟，并且可以在一锅序列中与溴化和 Pd 催化的交叉偶联相结合，以生成更多样化、高度取代的苯酚。
• COMPOUNDS AND THERAPEUTICAL USE THEREOF
  申请人：Cai Xiong Sui

  公开号：US20070244113A1

  公开（公告）日：2007-10-18

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳氨基喹唑啉及其类似物，可有效激活半胱氨酸蛋白酶并诱导细胞凋亡。本发明的化合物在治疗各种临床情况中具有用途，其中异常细胞的不受控制的生长和扩散。
• Compounds and therapeutical use thereof
  申请人：Cai Xiong Sui

  公开号：US20050137213A1

  公开（公告）日：2005-06-23

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳基氨基喹唑啉及其类似物，它们有效地激活半胱氨酸蛋白酶并诱导细胞凋亡。本发明的化合物在治疗各种临床病症中具有用途，其中发生异常细胞的不受控制的生长和扩散。
• Therapeutic amines
  申请人：Zeneca Limited

  公开号：US05866611A1

  公开（公告）日：1999-02-02

  Compounds of formula I, and their pharmaceutically acceptable salts, ##STR1## in which R.sup.1 and R.sup.2 are hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, phenylalkyl or alkenyl; or NR.sup.1 R.sup.2 is a heterocyclic group; A is trimethylene optionally substituted by alkyl and the phenyl ring is optionally substituted by substituents such as halogeno, alkenyl, amino, cyano, ureido, alkyl, carbamoylalkyl, alkanoylamino, alkoxycarbonyl, N-alkyl-alkanoylamino, alkanoyl and amines thereof; are inhibitors of squalene synthese and hence useful in treating diseases in which a lowering of cholesterol is desirable. As well as the use of these compounds in medicine, novel compounds, processes for their preparation and pharmaceutical compositions are also referred to.

  公式I的化合物及其药学上可接受的盐，其中R.sup.1和R.sup.2是氢，烷基，环烷基，环烷基烷基，苯基烷基或烯基; 或NR.sup.1 R.sup.2是杂环基; A是三亚甲基，可选择地被烷基取代，苯环可选择地被卤素，烯基，氨基，氰基，脲基，烷基，氨基甲酰基烷基，烷酰胺基，烷氧羰基，N-烷基-烷酰胺基，烷酰基和其胺基等取代基取代; 是角鲨烷合成酶的抑制剂，因此在治疗需要降低胆固醇的疾病方面有用。除了这些化合物在医学上的使用外，还提到了新化合物、它们的制备过程和制药组合物。
• COMPOUNDS AND THERAPEUTICAL USES THEREOF
  申请人：Myrexis, Inc.

  公开号：US20130029942A1

  公开（公告）日：2013-01-31

  Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳基氨基喹唑啉及其类似物，它们有效地激活半胱氨酸蛋白酶并诱导细胞凋亡。该发明的化合物在治疗各种临床病症中具有用途，其中包括发生异常细胞无控制生长和扩散的情况。